Project B8

Predicting patterns of adaptation to radio-chemotherapy in cancer

Reinhard Büttner, U Cologne | web | email

We study the evolution of cancers of the upper gastrointestinal tract in cell lines and patient-derived xenograft mice, generating comprehensive genome, transcriptome, and proteome data. Focusing on mutations in DNA repair pathways and their effects on future changes in the tumor, we will predict the likelihood of evolutionary trajectories towards therapy resistance in collaboration with projects B6 and B7.

Predictability in Evolution

Collaborative Research Center 1310

Publications

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma1

Quaas A., Heydt C., Gebauer F., Alakus H., Loeser H., Büttner R., Hillmer A., Bruns C., Merkelbach-Bruse S., Zander T., Frommolt P., Transl Oncol. 12: 154-161, 11. October 2018, https://doi.org/10.1016/j.tranon.2018.09.007

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Kron A., Alidousty C., Scheffler M., Merkelbach-Bruse S., Seidel D., Riedel R., Ihle M. A., Michels S., Nogova L., Fassunke J., Heydt C., Kron F., Ueckeroth F., Serke M., Krüger S., Grohe C., Koschel D., Benedikter J., Kaminsky B., Schaaf B., Braess J., Sebastian M., Kambartel K. O., Thomas R., Zander T., Schultheis A. M., Büttner R., Wolf J., Ann Oncol. 29: 2068-2075, 1. October 2018, https://doi.org/10.1093/annonc/mdy333

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations

Alidousty C., Baar T., Martelotto L. G., Heydt C., Wagener S., Fassunke J., Duerbaum N., Scheel A. H., Frank S., Holz B., Binot E., Kron A., Merkelbach-Bruse S., Ihle M. A., Wolf J., Büttner R., Schultheis A.M., J Pathol. 246: 67-76, 9. June 2018, https://doi.org/10.1002/path.5110

ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma

Schmitt A., Knittel G., Welcker D., Yang TP., George J., Nowak M., Leeser U., Büttner R., Perner S., Peifer M., Reinhardt HC., Cancer Res., 31. March 2017, https://doi.org/10.1158/0008-5472.CAN-16-3398

Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner

Jokić M., Vlašić I., Rinneburger M., Klümper N., Spiro J., Vogel W., Offermann A., Kümpers C., Fritz C., Schmitt A., Riabinska A., Wittersheim M., Michels S., Ozretić L., Florin A., Welcker D., Akyuz M.D., Nowak M., Erkel M., Wolf J., Büttner R., Schumacher B., Thomale J., Persigehl T., Maintz D., Perner S., Reinhardt H.C., Mol Cancer Res. Nov 14(11): 1110-1123, 11. August 2016, https://doi.org/10.1158/1541-7786.MCR-16-0094

imprint